Cardiol Therapeutics (CRDL) Cash from Operations (2020 - 2026)

Cardiol Therapeutics has reported Cash from Operations for 7 years, with the latest figure at 5481899.32 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 9.96% year-over-year to 5481899.32; the trailing twelve-month figure through Mar 2026 stood at 17545050.36 (up 3.47% YoY), and the FY2025 full-year result was 17105842.3, up 4.65% from the prior year.
• Cash from Operations for Q1 2026 stood at 5481899.32, down from 3746989.52 in the prior quarter.
• The five-year high for Cash from Operations was 1298440.3 in Q3 2022, with the low at 9242330.31 in Q4 2022.
• Historically, Cash from Operations has averaged 4722016.0 across 5 years, with a median of 4748595.89 in 2023.
• The largest YoY upside for Cash from Operations was 74.4% in 2022 against a maximum downside of 191.52% in 2022.
• Cardiol Therapeutics' Cash from Operations stood at 9242330.31 in 2022, then soared by 48.62% to 4748595.89 in 2023, then grew by 15.68% to 4003953.99 in 2024, then grew by 6.42% to 3746989.52 in 2025, then slumped by 46.3% to 5481899.32 in 2026.
• The last three Cash from Operations figures came in at 5481899.32 (Q1 2026), 3746989.52 (Q4 2025), and 5031955.39 (Q3 2025), per Business Quant data.